Radiation therapy firm Accuray has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Lung Optimized Treatment, a new component on the company's CyberKnife VSI system.
The new technology is designed to facilitate treatment of tumors throughout the lung without having to implant fiducial markers, according to the Sunnyvale, CA-based vendor. It uses simulation and comparison workflow, combined with tracking modes, to provide clinicians with multiple noninvasive treatment options, Accuray said.
Related Reading
Accuray revenues slump in Q1, November 9, 2010
Accuray expands CyberKnife service program, October 29, 2010
Accuray wins Czech Republic contract, October 14, 2010
Accuray hits CyberKnife milestone, October 6, 2010
Accuray wins French CyberKnife contract, September 3, 2010
Copyright © 2010 AuntMinnie.com
